BACKGROUND Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce low-density
This study was designed to explore the effects of reducing LDL-C to low values with alirocumab and included laboratory tests for parameters that rely on cholesterol metabolism and could potentially be affected by low LDL-C levels: gonadal hormones, fatsoluble vitamins, and adrenal function (these parameters were not measured in the other studies) (5).
The other phase 3 studies mainly recruited patients with either heterozygous familial hypercholesterolemia (HeFH) or high cardiovascular risk nonfamilial hypercholesterolemia who had LDL-C $70 or $100 mg/dl, depending on history of coronary heart disease or risk equivalents. In these trials, the starting alirocumab dose of 75 mg Q2W was increased to 150 mg Q2W at week 12 if pre-defined LDL-C levels
were not achieved at week 8. The exception was Robinson et al.
Safety of LDL-C <25 mg/dl With Alirocumab The rationale for the dosing strategy was as follows. The 150 mg Q2W dose was selected for maximal efficacy, corresponding to full saturation of the PCSK9 inactivation site. Because not all patients need the level of efficacy obtained with 150 mg Q2W to obtain their pre-specified LDL-C target of <70 or <100 mg/dl, the 75-mg dose was developed to provide on average a 50% reduction in LDL-C.
Patients were randomized to receive double-blind treatment with either alirocumab or control (placebo or ezetimibe) in addition to stable background statin Robinson et al. The safety of low-density lipoprotein cholesterol (LDL-C) levels <25 mg/dl was assessed using data from 14 randomized, controlled trials of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. AE ¼ adverse event; BMI ¼ body mass index; HbA1c ¼ glycated hemoglobin; HDL-C ¼ high-density lipoprotein cholesterol; HeFH ¼ heterozygous familial hypercholesterolemia; Q2W ¼ every 2 weeks.
Robinson et al.
Safety of LDL-C <25 mg/dl With Alirocumab Table 1 ). Median exposure to randomized treatment was 78 weeks in both the control and alirocumab groups, as well as in those with LDL-C <25 and <15 mg/dl ( Table 1) . The median time to the first LDL-C Robinson et al. Patients who had LDL-C <25 mg/dl were more often male, had cardiovascular disease or type 2 diabetes, and had higher baseline triglycerides, lower high-density lipoprotein cholesterol levels, and higher glycated hemoglobin levels ( Table 1) .
These characteristics (except for glycated hemoglobin and type 2 diabetes) were also associated with LDL-C <25 mg/dl in multivariate analysis (Online Table 2 ). Similar characteristics were identified for the 15 mg/dl threshold (Online Table 3 ). Conversely, in those with LDL-C <25 mg/dl, the proportion of patients with HeFH was lower (although this was not seen in the multivariate analysis), and lipoprotein(a) levels were lower. Baseline use of high-intensity statins or other LLT was not associated with LDL-C <25 mg/dl.
TEAEs IN PATIENTS WITH LDL-C <25 mg/dl. In the pooled analysis of phase 2 and 3 studies, overall rates of TEAEs, serious TEAEs, deaths, and discontinuations appeared similar for patients with LDL-C <25 mg/dl compared with those with LDL-C $25 mg/dl ( Table 2) . TEAEs appeared similar in those with <15 mg/dl and when compared with the overall pooled alirocumab and control populations ( Table 2) . Individual TEAEs occurring in $1% in any pooled group are shown in Online Table 4 . Despite significant differences in the baseline characteristics of patients with LDL-C <25 and $25 mg/dl, no imbalances in TEAE rates were identified among patients with LDL-C <25 or <15 mg/dl compared with those who did not achieve those LDL-C levels for neurocognitive, neurological (including peripheral neuropathy), musculoskeletal, ophthalmological, and hepatic events ( Table 2) .
A numerically higher incidence (rate per 100 patient-years) of cataracts was observed in patients with LDL-C <25 mg/dl versus those with higher LDL-C values (2.0 vs. 0.6) ( Table 2 ). In the propensity analysis, when controlling for baseline factors predictive of developing LDL-C <25 mg/dl, the rate of cataracts remained higher in patients with LDL-C <25 mg/dl (2.6%) versus $25 mg/dl (0.8%; hazard ratio: 3.40; 95% confidence interval: 1.58 to 7.35) ( Table 3) .
However, there was no difference between the overall alirocumab and control groups for cataracts ( Table 2) . <25 mg/dl ( Table 3) . Nor did propensity analyses reveal any differences in the rates of neurocognitive, neurological, ophthalmologic (other than cataracts), or hepatic events in those with LDL-C <25 mg/dl (Table 3 ). LABORATORY ANALYSES. In the laboratory analyses performed in ODYSSEY LONG TERM, alirocumab had no clinically meaningful effect on levels of cortisol or gonadal hormones (Online Table 5 ) or levels of Values are % (n) or % (n) [rate per 100 patient-years]. TEAEs were encoded as PTs using the MedDRA (version 18.0) according to the verbatim account entered by the investigator. TEAEs were further categorized according to standard MedDRA definitions (HLT, HLGT, and SMQ) or using custom groupings (CMQs) as defined by the study sponsors. Rate per 100 patient-years was calculated as number of patients with an events divided by total patient-years. For patients with events, number of patient-years was calculated up to the date of the first event; for patients without events, it was calculated up to the end of the TEAE period. For patients with LDL-C <25 mg/dl, the number of patient-years was calculated from the time of the first such value. *p ¼ 0.0018 for comparison of LDL-C $25 versus <25 mg/dl groups in pool of phase 3 studies. All other comparisons of AEs of interest were not significant ( Table 3) . †Only TEAEs that occurred, worsened, or became serious on the day or after the first of 2 consecutive LDL-C values <25 or <15 mg/dl were considered. ‡Selection of PTs based on SMQs: "demyelination" (broad þ narrow), "peripheral neuropathy" (broad þ narrow) and "Guillain-Barre syndrome" (broad þ narrow) excluding the following PTs ("acute respiratory distress syndrome," "asthenia," "respiratory arrest," and "respiratory failure"). §Selection of PTs is based on the HLGTs "deliria (including confusion)," "cognitive and attention disorders and disturbances," "dementia and amnestic conditions," "disturbances in thinking and perception," and "mental impairment disorders." kSelection of PTs is based on the SMQs "optic nerve disorders" (broad þ narrow), "retinal disorders" (narrow), and "corneal disorders" (narrow). ¶Selection of PTs is based on the HLT "cataract conditions." #Selection of PTs is based on HLGT "diabetic complications," HLT "diabetes mellitus," and HLT "carbohydrate tolerance analyses (including diabetes)," excluding PT "blood glucose decreased" and PT "hyperglycemia."
AE ¼ adverse event; CMQ ¼ Company MedDRA Query; HLGT ¼ high-level group term; HLT ¼ high-level term; LDL-C ¼ low-density lipoprotein cholesterol; MedDRA ¼ Medical Dictionary for Regulatory Activities; PT ¼ preferred term; SMQ ¼ Standardized MedDRA Query; SAE ¼ serious adverse event; TEAE ¼ treatment-emergent adverse event.
fat-soluble vitamins A, D, and K ( Table 4 ). An increase in levels of vitamin E adjusted for LDL-C was observed in the alirocumab group (Table 4) .
There were no cases of confirmed Hy's law elevations in hepatic enzymes or hemolytic anemia. Similarly, renal function as assessed by estimated glomerular filtration rate did not appear to be affected by LDL-C <25 or <15 mg/dl (Online Table 6 ). Nor did LDL-C <25 or <15 mg/dl appear to have an effect on mean glycated hemoglobin levels over time, regardless of baseline diabetes status (Online Figure 1) .
COMPARISON OF CALCULATED VERSUS MEASURED
LDL-C. In a correlation analysis comparing LDL-C values derived by calculation and beta quantification, only minor differences were observed between the 2 methods. In patients with LDL-C in the range of 15 to <25 mg/dl as measured by beta quantification, there was a median difference of 3.5 mg/dl compared with LDL-C values derived by calculation; in those with measured LDL-C <15 mg/dl, there was a median 3 mg/dl difference ( Table 5) . Values are % (n). *p ¼ 0.0018. All other comparisons were not significant. For definitions of these categories, see Table 2 .
CI ¼ confidence interval; HR ¼ hazard ratio; LDL-C ¼ low-density lipoprotein cholesterol. Absolute difference is defined as (calculated LDL-C À measured LDL-C). Percentage difference is defined as (calculated LDL-C À measured LDL-C)/measured LDL-C Â 100. Data are pooled from phase 3 studies.
LDL-C ¼ low-density lipoprotein cholesterol. Values are mean AE SD or % (n/N). Vitamin E levels were adjusted for LDL-C to more accurately assess vitamin E levels (25) . Safety of LDL-C <25 mg/dl With Alirocumab
